Sitting is bad for your health and exercise doesn’t seem to offset the harmful effects 
Food prices will climb everywhere as temperatures rise due to climate change – new research 
Some women’s breasts can’t make enough milk, and the effects can be devastating 
Japan Posts 7.7% Growth in Machinery Orders 
The hidden racist history of hair loss 
How cuts to marginal income tax could boost the UK’s stagnant economic growth 
Mentorship is key to improving social and economic outcomes for Black youth 
The idea that US interest rates will stay higher for longer is probably wrong 
OpenAI Announces Opening of Its First Office in Asia, Rolls out GPT-4 Optimized for Japanese Users 
Honey is said to help with hay fever symptoms – here’s what the research says about this claim 
General practice is in crisis in the UK – and it’s failing the people who need it most 
SK on, Siemens Partner to Build Smart Factory System for Battery Plants 
Could ADHD drugs reduce the risk of early death? Unpacking the findings from a new Swedish study 
To stop teenagers vaping they need to see it as cringe, not cool 
Personalized cancer treatments based on testing drugs quickly leads to faster treatment, better outcomes 
Why is toddler milk so popular? Follow the money 
Novavax raised doubts about the feasibility of continuing its business after struggles in rolling out its coronavirus jab although it has enough money to fund operations.
The COVID-19 vaccine maker, which described the situation as "subject to significant uncertainty," also announced plans to cut spending
On Tuesday, the company reported a loss of $182 million in the fourth quarter, after posting weaker sales than expected at $357 million.
Consequently, Novavax shares plummeted 25 percent in extended trading.
Novavax is currently gearing up for a fall vaccination campaign and said it plans to focus on delivering an updated COVID-19 vaccine.
The Maryland-based Novavax was an early frontrunner in the global vaccine race but fell behind after being hit by manufacturing and regulatory delays.
The company faced delays in regulatory submissions for its jab, which was only authorized in the US in July last year.
Before that, it received authorization from the European Union, United Kingdom, Canada, and Australia.
